Condor Capital Management Sells 6,607 Shares of Johnson & Johnson $JNJ

Condor Capital Management reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 49.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,657 shares of the company’s stock after selling 6,607 shares during the period. Condor Capital Management’s holdings in Johnson & Johnson were worth $1,762,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Wellington Management Group LLP increased its position in Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after buying an additional 2,513,321 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Johnson & Johnson by 8.5% during the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after acquiring an additional 1,225,676 shares during the period. Fisher Asset Management LLC increased its holdings in Johnson & Johnson by 11.5% in the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock worth $3,927,981,000 after acquiring an additional 1,530,070 shares during the last quarter. Amundi increased its holdings in Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after acquiring an additional 2,001,139 shares during the last quarter. Finally, Jupiter Topco LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at about $1,967,399,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 13,072 shares of the stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,832,923.66. This represents a 43.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on JNJ. Sanford C. Bernstein set a $270.00 price objective on shares of Johnson & Johnson in a report on Thursday, October 15th. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research note on Monday, August 3rd. Finally, Citigroup increased their target price on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Get Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Stock Up 0.0%

JNJ stock opened at $285.78 on Monday. The stock has a 50-day simple moving average of $266.97 and a two-hundred day simple moving average of $249.85. Johnson & Johnson has a twelve month low of $193.55 and a twelve month high of $288.11. The firm has a market capitalization of $687.95 billion, a PE ratio of 43.30, a PEG ratio of 2.82 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the prior year, the firm posted $2.80 earnings per share. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is 81.21%.

Key Stories Impacting Johnson & Johnson

These are some of the JNJ stories that stood out recently:

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.